Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for Apellis Pharmaceuticals (APLS) over the last 8 years, with Dec 2024 value amounting to -$197.9 million.

  • Apellis Pharmaceuticals' Net Income towards Common Stockholders rose 475.46% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of -$197.9 million for FY2024, which is 62.57% up from last year.
  • Apellis Pharmaceuticals' Net Income towards Common Stockholders amounted to -$197.9 million in FY2024, which was up 62.57% from -$528.6 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$197.9 million in FY2024 and a low of -$746.4 million during FY2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$528.6 million (2023), whereas its average is -$459.6 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Net Income towards Common Stockholders tumbled by 116.41% in 2021, and later surged by 62.57% in 2024.
  • Apellis Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$344.9 million in 2020, then slumped by 116.41% to -$746.4 million in 2021, then increased by 12.62% to -$652.2 million in 2022, then climbed by 18.94% to -$528.6 million in 2023, then spiked by 62.57% to -$197.9 million in 2024.